Apolipoprotein E ε4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease

被引:0
作者
Lasser, RA
Dukoff, R
Levy, J
Levin, R
Lehtimaki, T
Seubert, P
Sunderland, T
机构
[1] NIMH, Geriatr Psychiat Branch, Bethesda, MD 20892 USA
[2] Univ Tampere, Dept Clin Chem, FIN-33101 Tampere, Finland
[3] Athena Neurosci, San Francisco, CA USA
关键词
apolipoprotein E; Alzheimer's disease; tau; cognition; CSF;
D O I
10.1002/(SICI)1099-1166(1998110)13:11<767::AID-GPS866>3.0.CO;2-F
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
To better define the influence of apolipoprotein E (ApoE) epsilon 4 genotype on the cognitive and biochemical features of Alzheimer's disease (AD), cross-sectional analysis of global cognitive measures and cerebrospinal fluid studies gathered on AD subjects at a tertiary care facility between 1986 and 1997 was carried out. The 112 AD patients examined included 62 women and 50 men with a mean (SD) age of 64.2 (9.2) years. Patient demographics, illness onset age and duration, education level and global cognitive measures were recorded systematically. Genetic analysis for ApoE allele type and biochemical characterization of CSF, including total tau concentration, was performed. Descriptive statistics of demographics, cognitive and CSF measures were performed by chi-square, ANOVA and Tukey's tests. Overrepresentation of the epsilon 4 allele was found, with 45.5% of AD patients heterozygous and 20.5% homozygous for ApoE epsilon 4. Overall, ApoE epsilon 4 status had no effect on mean onset age of AD (F = 1.56; p = 0.214), but an earlier mean onset age of AD (F = 4.10; p = 0.02) was seen in the late-onset subjects. No differences were found with regard to ApoE epsilon 4 status and measures of disease, duration of illness or global cognitive performance. Although CSF tau was elevated in our sample (575.4 +/- 290.3 pg/ml), ApoE epsilon 4 status did not influence total CSF tau or neurotransmitter metabolite levels. ApoE epsilon 4 genotype had no impact on a variety of illness severity, cognitive and CSF examinations in the largest cross-sectional analysis of AD subjects yet reported. (C) 1998 US Government.
引用
收藏
页码:767 / 774
页数:8
相关论文
共 65 条
[1]  
[Anonymous], 1955, MANUAL WECHSLER ADUL
[2]  
Arai H, 1997, GERONTOLOGY, V43, P2
[3]   Effect of genetic risk factors and disease progression on the cerebrospinal fluid tau levels in Alzheimer's disease [J].
Arai, H ;
Terajima, M ;
Miura, M ;
Higuchi, S ;
Muramatsu, T ;
Matsushita, S ;
Machida, N ;
Nakagawa, T ;
Lee, VMY ;
Trojanowski, JQ ;
Sasaki, H .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1997, 45 (10) :1228-1231
[4]   TAU IN CEREBROSPINAL-FLUID - A POTENTIAL DIAGNOSTIC MARKER IN ALZHEIMERS-DISEASE [J].
ARAI, H ;
TERAJIMA, M ;
MIURA, L ;
HIGUCHI, S ;
MURAMATSU, T ;
MACHIDA, N ;
SEIKI, H ;
TAKASE, S ;
CLARK, CM ;
LEE, VMY ;
TROJANOWSKI, JQ ;
SASAKI, H .
ANNALS OF NEUROLOGY, 1995, 38 (04) :649-652
[5]   APOLIPOPROTEIN EPSILON-4 ALLELE AND DISEASE PROGRESSION IN PATIENTS WITH LATE-ONSET ALZHEIMERS-DISEASE [J].
BASUN, H ;
GRUT, M ;
WINBLAD, B ;
LANNFELT, L .
NEUROSCIENCE LETTERS, 1995, 183 (1-2) :32-34
[6]   CSF NEUROTRANSMITTER MARKERS IN ALZHEIMERS-DISEASE [J].
BEAL, MF ;
GROWDON, JH .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1986, 10 (3-5) :259-270
[7]  
Benjamin R, 1996, NEURODEGENERATION, V5, P43
[8]   SIGNIFICANCE OF DECREASED LUMBAR CSF LEVELS OF HVA AND 5-HIAA IN ALZHEIMERS-DISEASE [J].
BLENNOW, K ;
WALLIN, A ;
GOTTFRIES, CG ;
LEKMAN, A ;
KARLSSON, I ;
SKOOG, I ;
SVENNERHOLM, L .
NEUROBIOLOGY OF AGING, 1992, 13 (01) :107-113
[9]   Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele epsilon 4 during 14 months follow-up [J].
Blomberg, M ;
Jensen, M ;
Basun, H ;
Lannfelt, L ;
Wahlund, LO .
NEUROSCIENCE LETTERS, 1996, 214 (2-3) :163-166
[10]   Apolipoprotein E genotype in the prediction of cognitive decline and dementia in a prospectively studied elderly population [J].
Brayne, C ;
Harrington, CR ;
Wischik, CM ;
Huppert, FA ;
Chi, LY ;
Xuereb, JH ;
OConnor, DW ;
Paykel, ES .
DEMENTIA, 1996, 7 (03) :169-174